

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10694243
	Filing Date		2003-10-27
	First Named Inventor	Gang Bao	
	Art Unit	1618	
	Examiner Name	Dameron Levest Jones	
Attorney Docket Number		17625-0058	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button. [Add](#)

NON-PATENT LITERATURE DOCUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ts

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10694243
Filing Date	2003-10-27
First Named Inventor	Gang Bao
Art Unit	1618
Examiner Name	Dameron Levest Jones
Attorney Docket Number	17625-0058

1	Allvisatos et al., 1996, "Organization of 'Nanocrystal Molecules' Using DNA," Nature 382, 609-611.	<input type="checkbox"/>
2	Allvisatos et al., 1996, "Semiconductor Clusters, Nanocrystals, and Quantum Dots," Science 271:933-937.	<input type="checkbox"/>
3	Becker-Hapak, et al., 2001, "TAT-Mediated Protein Transduction into Mammalian Cells," Methods. 24, 247-256.	<input type="checkbox"/>
4	Bonnet et al., 1998, "Kinetics of Conformational Fluctuations in DNA Hairpin-Loops," Proc. INatl. Acad. Sci., 95:8602-8606.	<input type="checkbox"/>
5	Bruchez, Jr. et al., 1998, "Semiconductor Nanocrystals as Fluorescent Biological Labels," Science 281, 2013-2015.	<input type="checkbox"/>
6	Bulte, et al. 1992, "Specific MR Imaging of Human Lymphocytes by Monoclonal Antibody-Guided Dextra-Magnetite Particles," Magn. Reson. Med. 25, 148-157.	<input type="checkbox"/>
7	Bulte, et al., 1997, "Magnetic Nanoparticles as Contrast Agents for MR Imaging," In Scientific and clinical applications of magnetic carriers. (Editors: Hafeeli, U. et al.) Plenum Press, New York, pp 527-543.	<input type="checkbox"/>
8	Bulte, et al., 2001, "Magnetodendrimers Allow Endosomal Magnetic Labeling and in vivo Tracking of Stem Cells," Nat. Biotechnol. 19, 1141 - 1147.	<input type="checkbox"/>
9	Butterworth et al., 2001, "Preparation of Ultrafine Silica- and PEG-coated Magnetite Particles," Colloids and Surfaces A-Physicochemical and Engineering Aspects, 179:93-102.	<input type="checkbox"/>
10	Chan, et al., 1998, "Quantum Dot Bioconjugates for Ultrasensitive Nonisotopic Detection," Science 281, 2016-2018.	<input type="checkbox"/>
11	Chen et al., 2000, "Molecular Beacons: A Real-Time Polymerase Chain Reaction Assay for Detecting Salmonella," Analytical Biochem 280:166-172.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10694243
Filing Date	2003-10-27
First Named Inventor	Gang Bao
Art Unit	1618
Examiner Name	Dameron Levest Jones
Attorney Docket Number	17625-0058

12	Coriou, 1999, "Relaxivities of Different Superparamagnetic Particles for Application in NMR Tomography," J Magn Magn Mater 201, 449-452.	<input type="checkbox"/>
13	De Baar et al., 2001, "One-Tube Real-Time Isothermal Amplification Assay to Identify and Distinguish Human Immunodeficiency Virus Type 1 Subtypes A, B, and C and Circulating Recombinant Forms AE and AG," J. of Clin. Microbiology, 39(5):1895-1902	<input type="checkbox"/>
14	Dressman et al., 2003, "Transforming Single DNA Molecules into Fluorescent Magnetic Particles for Detection and enumeration of Genetic Variations," PNAS, 100(15): 8817-8822.	<input type="checkbox"/>
15	Dubertret et al., 2001, "Single-Mismatch Detection Using Gold-Quenched Fluorescent Oligonucleotides," Nature Biotechnol. 19, 365-370.	<input type="checkbox"/>
16	Dyal et al., 2003, "Activity of Candida rugosa Lipase Immobilized on gamma-Fe2O3 Magnetic Nanoparticles, J And Chem 125: 1684-1685.	<input type="checkbox"/>
17	Eilghanian et al., 1997, "Selective Colorimetric Detection of Polynucleotides Based on the Distance-Dependent Optical Properties of Gold Nanoparticles," Science 277, 1078-1081.	<input type="checkbox"/>
18	Fang et al., 2000, "Using Molecular Beacons to Probe Molecular Interactions Between Lactate Dehydrogenase and Single-Stranded DNA," Anal. Chem., 72:3280-3285.	<input type="checkbox"/>
19	Goddard et al., 2000, "Sequence Dependent Rigidity of Single Stranded DNA," Phys Rev. Lett 85:2400-2403.	<input type="checkbox"/>
20	Han et al., 2001, "Quantum-dot-Tagged Microbeads for Multiplexed Optical Coding of Biomolecules," Nature Biotechnol. 19, 631-635.	<input type="checkbox"/>
21	Harris et al., 2001, "Traumatic Brain Injury-Induced Changes in Gene Expression and Functional Activity of Mitochondrial Cytochrome C Oxidase," J Neurotrauma 18, 993-1009.	<input type="checkbox"/>
22	Hogemann et al., 2000, "Improvement of MRI Probes to Allow Efficient Detection of Gene Expression," Bioconjugate Chem. 11:941-946	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10694243
Filing Date	2003-10-27
First Named Inventor	Gang Bao
Art Unit	1618
Examiner Name	Dameron Levest Jones
Attorney Docket Number	17625-0058

23	Huber et al., 1998, "Fluorescently Detectable Magnetic Resonance Imaging Agents," Bioconjugate Chem. 9:242-249.	<input type="checkbox"/>
24	Josephson et al., 1999, "High-Efficiency Intracellular Magnetic Labeling with Novel Superparamagnetic-Tat Peptide Conjugates," Bioconj. Chem. 10, 186-191.	<input type="checkbox"/>
25	Josephson et al., 2001, "Magnetic Nanosensors for the Detection of Oligonucleotide Sequences," Angew Chem Int Ed 40, 3204-3206.	<input type="checkbox"/>
26	Koenig et al., 1995, "Theory of 1/T1 and 1/T2 NMRD Profiles of Solutions of Magnetic Nanoparticles," Magn Reson Med 34, 227-233.	<input type="checkbox"/>
27	Kim et al., 2003, "Protective Coating of Superparamagnetic Iron Oxide Nanoparticles," Chem Matter 45: 1617-1627.	<input type="checkbox"/>
28	Kuhn et al., 2002, "Hybridization of DNA and PNA Molecular Beacons to Single-Stranded and Double-Stranded DNA Targets," J Am Chem Soc. 124, 1097-103.	<input type="checkbox"/>
29	Le Duc et al., 2001, "Ultrasmall Particulate Iron Oxides as Contrast Agents for Magnetic Resonance Spectroscopy: A Dose-Effect Study," J Magn Reson Imaging. 13, 619-26.	<input type="checkbox"/>
30	Lewin et al., 2000, "Tat Peptide-Derivatized Magnetic Nanoparticles Allow in vivo Tracking and Recovery of Progenitor Cells," Nat Biotechnol. 18, 410-4.	<input type="checkbox"/>
31	Liu et al., 2002, "Real-Time Monitoring in vitro Transcription Using Molecular Beacons," Analytical Chem., 300:40-45.	<input type="checkbox"/>
32	Liu et al., 1995, "Self-Assembled Monolayer Coatings on Nanosized Magnetic Particles Using 16-Mercaptohexadecanoic Acid," Langmuir, 11:4617-4622.	<input type="checkbox"/>
33	Louie et al., 2000, "In vivo Visualization of Gene Expression Using Magnetic Resonance Imaging," Nat Biotechnol. 18:321-325	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10694243
Filing Date	2003-10-27
First Named Inventor	Gang Bao
Art Unit	1618
Examiner Name	Dameron Levest Jones
Attorney Docket Number	17625-0058

34	Lu et al., 2002, "Modifying the Surface of Superparamagnetic Iron Oxide Nanoparticles through A Sol-Gel Approach," Nano Lett., 2(3):183-186.	<input type="checkbox"/>
35	Marras et al., 1999, "Multiplex Detection of Single-Nucleotide Variations Using Molecular Beacons," Gen. Analysis, 14:151-156.	<input type="checkbox"/>
36	Matsuo, 1998, "In situ Visualization of Messenger RNA for Basic Fibroblast Growth Factor in Living Cells," biochimica et Biophysica Acta 1379:178-184.	<input type="checkbox"/>
37	Mattoussi et al., 2000, "Self-Assembly of CdSe-ZnS Quantum Dot Bioconjugates Using an Engineered Recombinant Protein," J. Am. Chem. Soc. 122:12142-12150.	<input type="checkbox"/>
38	Mirkin et al., 1996, "A DNA-Based Method for Rationally Assembling Nanoparticles into Macroscopic Materials," Nature 382:607-609.	<input type="checkbox"/>
39	Mitchell et al., 1999, "Programmed Assembly of DNA Functionalized Quantum Dots," J. Am. Chem. Soc. 121:8122-8123.	<input type="checkbox"/>
40	Mitchell, 2001, "Turning the Spotlight on Cellular Imaging," Nat. Biotech., 19:1013-1017.	<input type="checkbox"/>
41	Molenaar et al., 2001, "Linear 2' O-Methyl RNA Probes for Visualization of RNA in Living Cells," Nucleic Acids Res. 29 (17):e89.1-10.	<input type="checkbox"/>
42	Nicewarner-Pena et al., 2001, "Submicrometer Metallic Barcodes," Science, 294:137-141.	<input type="checkbox"/>
43	Pathak et al., 2001, "Hydroxylated Quantum Dots as Luminescent Probes for in Situ Hybridization," J. Am. Chem. Soc. 123:4103-4104	<input type="checkbox"/>
44	Perez et al., 2002, "DNA-Based Magnetic Nanoparticle Assembly Acts as a Magnetic Relaxation Nanoswitch Allowing Screening of DNA-Cleaving Agents," J Am Chem Soc. 124:2856-2857	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10694243
Filing Date	2003-10-27
First Named Inventor	Gang Bao
Art Unit	1618
Examiner Name	Dameron Levest Jones
Attorney Docket Number	17625-0058

45	Reynolds et al., 2000, "Homogeneous, Nanoparticle-Based Quantitative Colorimetric Detection of Oligonucleotides," J. Am. Chem. Soc. 122:3795-3796.	<input type="checkbox"/>
46	Santra et al., 2001, "Synthesis and Characterization of Silica-Coated Iron Oxide Nanoparticles in Microemulsion: The Effect of Nonionic Surfactants," Langmuir 17: 290-2906.	<input type="checkbox"/>
47	Shen et al., 1993, "Monocrystalline Iron Oxide Nanocompounds (MION): Physicochemical Properties," Magn Reson Med 29, 599-604.	<input type="checkbox"/>
48	Sokol et al., 1998, "Real Time Detection of DNA-RNA Hybridization in Living Cells," Proc Natl Acad Sci USA 95:11538-11543.	<input type="checkbox"/>
49	Storhoff et al., 1999, "Programmed Materials Synthesis with DNA," Chem. Rev. 99:1849-1862.	<input type="checkbox"/>
50	Tsourkas et al., 2003, "Spectroscopic Features of Dual Fluorescence/Luminescence Resonance Energy-Transfer Molecular Beacons," Anal Chem. 75:3697-3703.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10694243
Filing Date	2003-10-27
First Named Inventor	Gang Bao
Art Unit	1618
Examiner Name	Dameron Levest Jones
Attorney Docket Number	17625-0058

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☒ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Kathryn H. Wade/	Date (YYYY-MM-DD)	2007-09-20
Name/Print	Kathryn H. Wade, Ph.D.	Registration Number	54682

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.